Reaction

Normocytic Anaemia reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,417 reports · 60 co-occurring drugs

As of the last recalculation, Normocytic Anaemia appears in 1,417 FAERS reports alongside 60 co-occurring drug terms. The strongest observed disproportionality signal is ALEMTUZUMAB (PRR 28.0).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Alemtuzumab	36	28.0	28.1
Anti-Thymocyte Globulin (Rabbit)	13	23.9	23.9
Nebivolol	18	16.8	16.8
Theophylline Anhydrous	12	14.3	14.3
Anakinra	16	14.3	14.3
Sirolimus	13	14.3	14.3
Daspone	9	13.7	13.7
Dapsone Gel, 5%	9	13.6	13.7
Levofloxacin	52	13.1	13.1
Levofloxacin In 5% Dextrose	52	13.1	13.1
Febuxostat Tablets 40 Mg	9	13.1	13.1
Febuxostat Tablets 80 Mg	9	13.1	13.1
Theophylline	10	12.9	12.9
Mycophenolate Mofetil	109	12.7	12.7
Mycophenolate Mofetil Hydrochloride	109	12.7	12.7
Dapsone	9	12.5	12.5
Tacrolimus Extended-Release Capsules	98	12.3	12.3
Rifampin	12	12.2	12.2
Tacrolimus Ointment 0.1%	96	12.1	12.1
Torsemide	26	11.7	11.7
Terbinafine Hydrochloride	7	11.6	11.6
Ganciclovir	8	11.5	11.5
Ganciclovir Sodium	8	11.2	11.2
Tacrolimus	110	11.1	11.1
Vibegron	6	11.0	11.0
Cefazolin Sodium	9	11.0	11.0
Valganciclovir Hydrochloride Powder,	9	10.9	10.9
Clopidogrel Bisulfate	72	10.8	10.8
Mycophenilic Acid	15	10.7	10.7
Valganciclovir	13	10.2	10.2
Valganciclovir Hydrochloride	13	10.2	10.2
Dextrose	9	10.1	10.1
Imatinib	12	10.1	10.1
Bleomycin Sulfate	7	10.0	10.0
Dextrose Monohydrate	9	9.9	10.0
Everolimus Tablets	11	9.7	9.7
Linezolid	19	9.5	9.5
Nebivolol Hydrochloride	21	9.3	9.3
Ceftriaxone	20	9.1	9.1
Ceftriaxone Sodium	23	8.9	8.9
Febuxostat	10	8.8	8.8
Ranolazine	6	8.5	8.5
Dabigatran Etexilate	43	8.4	8.4
Methoxy Polyethylene Glycol-Epoetin Beta	6	8.0	8.0
Apixaban	35	7.9	7.9
Remdesivir	7	7.7	7.8
Brimonidine Tartrate	9	7.5	7.5
Timolol	6	7.3	7.3
Travoprost	4	6.8	6.8
Carfilzomib	12	6.3	6.3
Dapagliflozin	13	6.1	6.1
Dabigatran Etexilate Mesylate	29	6.0	6.0
Daratumumab	16	5.9	5.9
Eculizumab	20	5.5	5.5
Encorafenib	3	4.5	4.5
Olaparib	6	4.2	4.2
Trifluridine And Tipiracil	3	4.1	4.1
Orlistat	7	4.0	4.0
Sacubitril And Valsartan	29	3.7	3.7
Lutetium Lu 177 Vipivotide Tetraxetan	3	3.3	3.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.